top of page

Stevanato Group will construct a manufacturing center in China



Stevanato Group (NYSE: STVN) (the "Company"), a global provider of drug containment and delivery and diagnostic solutions for the pharmaceutical, biotechnology and life science, today announced the acquisition of a facility in Zhangjiagang for the construction of a new facility, where the Company plans to begin renovations in the spring of 2022, as part of the latest phase of its expansion into China.


The new facility is located near the company's drug containment solutions facility in the Jiangsu Zhangjiagang Economic and Technological Development Zone, thereby helping to consolidate the area as a major center of biopharmaceutical innovation. 


The facility will come to cover approximately 32,000 square meters, including engineering space. The Company is expected to employ approximately 270 people in the Chinese hub. As a strategic hub for the Company's operations in the country, we believe the plant will support the Chinese pharmaceutical industry by streamlining the local drug development chain from the laboratory through commercialization and help meet the growing demand for biologics.


The state-of-the-art facility is expected to house (i) the production of high-value solutions, such as EZ-fill® pre-sterilized syringes and bottles to meet the growing market demand for biotechnology and vaccines, as well as (ii) an area for visual inspection machines and glass forming lines with state-of-the-art manufacturing processes and technologies. Production is expected to start in 2023, and the first EZ-fill® lines are expected to be operational in early 2024. In addition, the Company plans to expand its existing production of standard drug containment solutions in Zhangjiagang, increasing the size of the existing facility by approximately 7,000 square meters. 


This plant is expected to nearly double current production capacities by the end of 2024. “We are excited to continue our expansion in China as one of our strategic priorities to optimize our global footprint," said Franco Moro, CEO of the Company. "


The start of construction of our new manufacturing center is an important milestone. for Stevanato Group in a key market that will allow us to better serve local customers with superior drug containment solutions and machinery supply. "


On 10 March 2022, the Company will host an inaugural event to celebrate the new hub in the presence of the local authorities of Zhangjiagang and ZETDZ, representatives of the Italian consulate in China.



Source: Piombino Dese (PD), Italy - March 10, 2022 - Stevanato Group

Comments


bottom of page